Menu
CAR-T cells are the most clinically and commercially advanced of the anti-cancer cell therapies. While incredibly effective, they have faced multiple challenges.
At Nanotein work to address these challenges with our innovative reagents for CAR-T cell therapies help customers to avoid treatment manufacturing failures and the production of therapeutic doses that only deliver short lived and/or poor treatment outcomes.
Our technology is able to produce larger quantities of CAR-T cells in less time than competitor reagents.
We use protein-based components in our manufacturing, eliminating the risk of synthetic contaminants.
Clinical research showed high rates of tumor destruction and remission in patients by the types of T cell profile Nanotein’s product expands.
Our technology is able to produce larger quantities of CAR-T cells in less time than competitor reagents.
We use protein-based components in our manufacturing, eliminating the risk of synthetic contaminants.
Clinical research showed high rates of tumor destruction and remission in patients by the types of T cell profile Nanotein’s product expands.
Subscribe to Our Newsletter
